Status:
COMPLETED
Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV
Lead Sponsor:
Case Western Reserve University
Collaborating Sponsors:
Duke University
Metro Health, Michigan
Conditions:
HIV-1-infection
Hypertension
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Social distancing measures put in place to combat the COVID-19 disease pandemic may increase social isolation and impact cardiovascular disease prevention behaviors among people living with HIV (PLWH)...
Detailed Description
Social distancing in the context of the SARS-CoV-2 coronavirus and COVID-19 disease pandemic may amplify isolation and loneliness due to the requirement to limit in-person interactions with loved ones...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Confirmed HIV+ diagnosis
- Undetectable HIV viral load: defined as the most recent HIV viral load \<200 copies/mL, checked within the past year (assessed via chart abstraction)
- Hypertension: defined as systolic BP \>130 mmHg on ≥ 2 occasions in the past 12 months or on an antihypertensive medication (assessed via chart abstraction), and
Exclusion
- On anti-hypertensive medications solely for a non-hypertension indication (e.g. systolic heart failure),
- Severely hearing or speech impaired, or other disability that would limit participation in the intervention components, and
- In a nursing home and/or receiving in-patient psychiatric care.
- Terminal illness with life expectancy \< 4 months
- No reliable access to a telephone
- Pregnant, breast-feeding, or planning a pregnancy during the study period
- Planning to move out of the area in the next 12 months
- Non-English speaking
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 15 2023
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT04661813
Start Date
March 1 2021
End Date
January 15 2023
Last Update
October 24 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke Health
Durham, North Carolina, United States, 27710
2
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
3
MetroHealth Medical Center
Cleveland, Ohio, United States, 44109